Menu
Search
|

Menu

Close
X

OpGen Inc OPGN.OQ (NASDAQ Stock Exchange Capital Market)

2.03 USD
+0.17 (+9.14%)
As of Feb 16
chart
Previous Close 1.86
Open 1.88
Volume 91,269
3m Avg Volume 46,482
Today’s High 2.03
Today’s Low 1.88
52 Week High 31.25
52 Week Low 1.85
Shares Outstanding (mil) 4.92
Market Capitalization (mil) 9.99
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
2
FY16
4
FY15
3
EPS (USD)
FY17
-10.237
FY16
-28.355
FY15
-35.996
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
3.10
8.57
Price to Book (MRQ)
vs sector
1.12
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
36.70
15.12
LT Debt to Equity (MRQ)
vs sector
3.18
11.85
Return on Investment (TTM)
vs sector
-424.56
13.54
Return on Equity (TTM)
vs sector
-489.36
14.80

EXECUTIVE LEADERSHIP

Evan Jones
Chairman of the Board, Chief Executive Officer, Since 2015
Salary: $316,538.00
Bonus: --
Timothy Dec
Chief Financial Officer, Corporate Secretary, Since 2017
Salary: $273,462.00
Bonus: $50,000.00
Geoffrey McKinley
Senior Vice President - Research and Development and Business Development, Since 2015
Salary: --
Bonus: --
G. Terrance Walker
Senior Vice President - Research and Development, Since 2014
Salary: --
Bonus: --
Vadim Sapiro
Chief Information Officer, Since 2011
Salary: $280,385.00
Bonus: $50,500.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

708 Quince Orchard Rd Ste 205
GAITHERSBURG   MD   20878-1793

Phone: +1240.8131260
Site: opgen.com/

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.

SPONSORED STORIES